📊 CagriSema at a Glance
- Weight Loss: 15-20% average
- Mechanism: Amylin + GLP-1 dual agonist
- Status: Phase 3 trials (2026)
- Expected FDA Approval: 2027
- Manufacturer: Novo Nordisk (Wegovy maker)
What Is CagriSema?
CagriSema is Novo Nordisk's answer to Eli Lilly's tirzepatide (Zepbound/Mounjaro). It combines TWO peptides in one injection:
- Cagrilintide: Synthetic amylin analog that reduces appetite and slows gastric emptying
- Semaglutide: The GLP-1 agonist in Wegovy/Ozempic
Why combine them? Amylin and GLP-1 work through different pathways. Combined, they produce more weight loss than semaglutide alone—bringing Novo Nordisk closer to competing with tirzepatide's superior results.
CagriSema Weight Loss Results
Phase 2 Trial Data (2023)
- 15.6% average weight loss at 2.4mg semaglutide + 2.4mg cagrilintide
- ~37 pounds lost for a 240-pound person
- Better than semaglutide alone (10-15%) but less than tirzepatide (15-22.5%)
Phase 3 REDEFINE Trial (Ongoing 2026)
Novo Nordisk is testing higher doses. Industry analysts predict 18-20% weight loss results when Phase 3 data reports in late 2026.
How CagriSema Compares to Competitors
| Medication | Weight Loss | Availability |
|---|---|---|
| Retatrutide | 24-28.7% | 2027-2028 |
| Tirzepatide | 15-22.5% | Available now |
| CagriSema | 15-20% | 2027 (projected) |
| Semaglutide | 10-15% | Available now |
CagriSema Side Effects
Expected to be similar to semaglutide:
- Nausea (most common)
- Diarrhea or constipation
- Vomiting
- Reduced appetite
Potential difference: Amylin activation may cause slightly different GI effects than GIP (in tirzepatide), but early trials show similar tolerability.
When Will CagriSema Be Available?
- 2026: Phase 3 REDEFINE trial results expected
- Late 2026/Early 2027: FDA submission likely
- 2027: FDA approval projected
- 2027-2028: Commercial launch
Expected CagriSema Pricing
Novo Nordisk will likely price CagriSema competitively with tirzepatide:
- Brand-name: $900-1,400/month (similar to Wegovy/Zepbound)
- Compounded: $300-600/month (if allowed, depends on shortages)
Should You Wait for CagriSema?
Our take: No. CagriSema won't be dramatically better than existing options (tirzepatide, semaglutide). Here's what to do instead:
- Start tirzepatide NOW ($179-499/month compounded) - delivers similar or better results (15-22.5% vs CagriSema's 15-20%)
- Lose 30-50 pounds while CagriSema completes trials
- Switch to CagriSema or retatrutide in 2027-2028 if you plateau or want more options
Don't Wait for CagriSema - Start Tirzepatide Today
Tirzepatide delivers equal or better results (15-22.5%) and is available NOW for $179/month.
Start with MEDVi →Related: Retatrutide Guide | Retatrutide vs Tirzepatide